Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Barcelona Hepatic Hemodynamic Laboratory, IDIBAPS, CIBEREHD, Barcelona, Spain.
J Hepatol. 2015 Jan;62(1):83-91. doi: 10.1016/j.jhep.2014.07.031. Epub 2014 Aug 8.
BACKGROUND & AIMS: Most liver grafts undergoing transplantation derive from brain dead donors, which may also show hepatic steatosis, being both characteristic risk factors in liver transplantation. Ischemic preconditioning shows benefits when applied in non-brain dead clinical situations like hepatectomies, whereas it has been less promising in the transplantation from brain dead patients. This study examined how brain death affects preconditioned steatotic and non-steatotic liver grafts undergoing transplantation.
Steatotic and non-steatotic grafts from non-brain dead and brain dead-donors were cold stored for 6h and then transplanted. After 2, 4, and 16 h of reperfusion, hepatic damage was analysed. In addition, two therapeutic strategies, ischemic preconditioning and/or acetylcholine pre-treatment, and their underlying mechanisms were characterized.
Preconditioning benefits in non-brain dead donors were associated with nitric oxide and acetylcholine generation. In brain dead donors, preconditioning generated nitric oxide but did not promote acetylcholine upregulation, and this resulted in inflammation and damage. Acetylcholine treatment in brain dead donors, through PKC, increased antioxidants and reduced lipid peroxidation, nitrotyrosines and neutrophil accumulation, altogether protecting against damage. The combination of acetylcholine and preconditioning conferred stronger protection against damage, oxidative stress and neutrophil accumulation than acetylcholine treatment alone. These superior beneficial effects were due to a selective preconditioning-mediated generation of nitric oxide and regulation of PPAR and TLR4 pathways, which were not observed when acetylcholine was administered alone.
Our findings propose the combination of acetylcholine+preconditioning as a feasible and highly protective strategy to reduce the adverse effects of brain death and to ultimately improve liver graft quality.
大多数接受移植的肝移植物来自脑死亡供体,这些供体也可能表现出肝脂肪变性,两者都是肝移植的特征性危险因素。缺血预处理在非脑死亡的临床情况(如肝切除术)中具有益处,而在脑死亡患者的移植中则不太有希望。本研究探讨了脑死亡如何影响接受移植的预处理性脂肪变性和非脂肪变性肝移植物。
非脑死亡和脑死亡供体的脂肪变性和非脂肪变性移植物在冷储存 6 小时后进行移植。在再灌注 2、4 和 16 小时后,分析肝损伤。此外,还研究了两种治疗策略,即缺血预处理和/或乙酰胆碱预处理,及其潜在机制。
非脑死亡供体的预处理益处与一氧化氮和乙酰胆碱的产生有关。在脑死亡供体中,预处理产生了一氧化氮,但没有促进乙酰胆碱的上调,这导致了炎症和损伤。脑死亡供体中的乙酰胆碱治疗通过 PKC 增加了抗氧化剂并减少了脂质过氧化、硝基酪氨酸和中性粒细胞的积累,从而起到了保护作用。与单独使用乙酰胆碱治疗相比,乙酰胆碱和预处理的联合使用对损伤、氧化应激和中性粒细胞积累具有更强的保护作用。这些优越的有益效果归因于选择性预处理介导的一氧化氮生成和 PPAR 和 TLR4 途径的调节,而单独使用乙酰胆碱时则观察不到这些途径。
我们的研究结果提出了乙酰胆碱+预处理的联合使用作为一种可行且高度保护的策略,可以减少脑死亡的不良影响,并最终改善肝移植物的质量。